5. Documented negative serologic testing for human immunodeficiency virus (HIV), hepatitis B (unless serologically positive due to prior vaccination), and hepatitis C within the year prior to enrollment. If positive for HBV or HCV exposure or prior infection, can continue to participate in trial with prophylactic entecavir (for HBV) or monitoring for viral reactivation (for HCV).